3T Biosciences
3T Biosciences develops next-generation therapies for solid tumors and immune-mediated diseases using proprietary technology and machine learning, based in South San Francisco.
History
3T Biosciences was founded in 2017, originating from the research conducted in Dr. K. Christopher Garcia’s lab at Stanford University. The company is based in South San Francisco and began with a significant Series A financing round, raising $40 million to support its early development. From its inception, 3T Biosciences has focused on developing transformative therapies for the treatment of solid tumors and other immune-mediated diseases.
Proprietary Technology: 3T-TRACE
3T Biosciences employs a proprietary platform technology known as 3T-TRACE (T Cell Receptor Antigen and Cross-Reactivity Engine) for target discovery and therapeutic development. The 3T-TRACE platform integrates high-diversity target libraries with machine learning to identify novel targets and T cell receptors (TCRs). This technology aims to create specific, safer, and more effective therapies for a broad patient population by leveraging comprehensive profiling of TCR specificity.
Partnerships
3T Biosciences has entered into strategic partnerships to enhance its research and development efforts. Notably, the company has a second partnership with Boehringer Ingelheim, focused on developing next-generation cancer immunotherapies. These collaborations support 3T Biosciences’ goal of advancing innovative treatments for cancer and other immune-mediated diseases.
Therapeutic Modality
3T Biosciences develops multiple therapeutic modalities, encompassing T cell receptor mimetics (TCRm) bispecifics, peptide vaccines, and novel TCR cell therapies. The company also explores therapies for autoimmune diseases and viral infections. By leveraging its proprietary 3T-TRACE platform and data science, bioinformatics, and engineering capabilities, 3T Biosciences advances its diverse therapeutic pipeline with the aim of addressing significant unmet medical needs.
Use of Machine Learning
The 3T-TRACE platform at 3T Biosciences utilizes machine learning algorithms to facilitate high-throughput and comprehensive profiling of TCR specificity. This integration of machine learning enhances the accuracy and efficiency of target discovery and therapeutic development. The use of advanced data science techniques allows 3T Biosciences to rapidly identify shared targets and therapeutically active T cell receptors (TCRs).